Features
Get A Demo
Plans
Sign Up
Login
All Federal Contract IDV Awards
Help
Indefinite Delivery Contract HHSN275201300024I
Award Date
8/15/13
Last Date to Order
8/31/20
Overview
🤔 AI Insights
Buyer Personas
Industry Personas
Buyer Personas In this Market
Activity
6
Contract IDVs
Contract Awards
7
Transactions
6
Price Lists
Opportunity Stack
1
Federal Agency
National Institute of Child Health and Human Development
Awardee
Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
PSC Category
AN12 - Health R&D Services; Health Care Services; Applied Research
Federal Contract Vehicle
NICHD Contraceptive Clinical Trials Network
Pricing Type
Cost No Fee
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
NICHD Contraceptive Clinical Trials Network
Master IDIQ
HHSN275201300024I
Indefinite Delivery Contract
7
Federal Contract Awards
Description
Update #1
Update #2
Update #3
NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK - MALE SITES
Posted 8/15/13, 12:00 AM
Mod #
Description
Reason For Modification
Federal Obligation
(Click to sort descending)
Date
(Click to sort ascending)
P00005
NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK - MALE SITES
Other Administrative Action
$0
11/4/22
P00004
EO14042 NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK - MALE SITES
Other Administrative Action
$0
11/4/21
P00003
NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK - MALE SITES
Other Administrative Action
$0
8/24/20
P00002
NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK - MALE SITES
Vendor DUNS or Name Change - Non-Novation
$0
10/31/19
P00001
NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK - MALE SITES
Other Administrative Action
$0
8/26/19
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
Delivery Order HHSN275201300024I-HHSN27500007
This is a $11,791,957.00 delivery order contract awarded by the National Institute of Child Health and Human Development (NICHD) to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The contract is part of the NICHD Contraceptive Clinical Trials Network and supports the Contraceptive Efficacy Clinical Trial - Male Sites program. The Lundquist Institute, an independent non-profit research organization, will conduct clinical trials to evaluate new male contraceptive products that have undergone successful preclinical testing. This contract does not have a set-aside designation. The Lundquist Institute frequently serves as a prime contractor and subcontractor on federal research contracts and grants across a wide range of biomedical topics.
Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center
$11.8m
9/14/15
12/31/25
9/25/24
Delivery Order HHSN275201300024I-HHSN27500003
CONTRACEPTIVE CLINICAL TRIAL NETWORK - MALE - NESTES TASK ORDER 3 CENTRAL LAB CONTRACT # HHSN275201300024I/HHSN00003
Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center
$332.9k
2/12/14
3/29/17
2/9/16
Delivery Order HHSN275201300024I-HHSN27500004
Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center is delivering a 28 Day Study under a $2,099,607.44 potential value task order against the National Institutes of Health National Institute of Child Health and Human Development's Contraceptive Clinical Trials Network indefinite delivery contract. The contract has no set-aside designation. As the prime contractor, Lundquist Institute will conduct this clinical trial through December 31, 2021 to evaluate male contraceptive products that have undergone successful preclinical testing. This supports the agency's Contraceptive Clinical Trials Networks - Male Studies program goals to potentially expand contraceptive options following evaluation of candidates through the clinical trial process.
Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center
$2.1m
9/25/14
12/31/21
1/31/24
Delivery Order HHSN275201300024I-HHSN27500005
NES TES 28 DAY STUDY
Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center
$1.0m
9/25/14
12/31/17
6/30/17
Delivery Order HHSN275201300024I-HHSN27500002
This is a delivery order contract awarded by the National Institute of Child Health and Human Development (NICHD) to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, a non-profit research organization. The contract, with a ceiling value of $2,795,103, is part of the NICHD Contraceptive Clinical Trials Network and supports the Male Contraceptive Trials topic area. The work involves evaluating products that have undergone successful preclinical testing for the development of new male contraceptive options through clinical research. This delivery order contract has a period of performance ending on November 30, 2024. The contract was awarded on an unrestricted basis without any set-aside designation.
Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center
$2.8m
12/31/13
11/30/24
9/18/24
Name
Description
Solicitation Number
Federal Agency
Type
Posted Date
(Click to sort descending)
NICHD Contraceptive Clinical Trials Network - Male Sites
Added: Apr 02, 2012 4:27 pm THIS IS NOT A REQUEST FOR PROPOSALS (RFP). THIS IS A PRE-SOLICITATION ANNOUNCEMENT ONLY. A REQUEST FOR PROPOSALS WILL BE ISSUED VIA FEDBIZOPPS ON OR ABOUT APRIL 17, 2012.The National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is planning to issue an RFP for multiple Indefinite/Delivery, Indefinite/Quantity (IDIQ) Task Order contracts for the NICHD Contraceptive Clinical Trials Network (CCTN). The NIH, NICHD is the lead Federal agency for the conduct of basic, clinical and epidemiological research to develop new contraceptives and to evaluate existing methods of contraception and reproductive health. The Center for Population Research (CPR), within NICHD, was established in 1968 by the Secretary of Health Education and Welfare, with the important goal of developing new contraceptives through the use of contracts and grants. Within CPR, the Contraception and Reproductive Health Branch (CRHB) has long supported several preclinical contraceptive testing facilities, as well as facilities for chemical and peptide synthesis. To further expand their contraceptive development capabilities, in 1996 CRHB established the initial NICHD CCTN in order to conduct Phase I, II, and III clinical trials of new contraceptive methods.The NICHD CCTN is an important component of the CRHB contraceptive development capability. Products that have undergone formulation and successful pre-clinical testing, either through the CRHB formulation and testing facilities or through outside sources, are candidates for clinical testing in the NICHD CCTN. The NICHD CCTN is particularly valuable for providing a venue for testing new contraceptive drugs and devices that have been developed by small companies that lack the resources to support large-scale clinical trials.This acquisition is for a re-competition of the male sites that will operate under an Indefinite/Delivery, Indefinite/Quantity (IDIQ) Task Order contracts. The male sites will be able to work with the CCTN Statistical and Clinical Coordinating Center (SCCC) and NICHD to rapidly develop protocols and initiate clinical trials shortly after candidate products have completed the necessary preclinical testing. The resultant IDIQ contracts will be for a seven (7) year period of performance. The CCTN male sites contractors will evaluate systematically the safety and efficacy of new male contraceptive drugs and devices as well as drug treatments for conditions in Phase I, II, III and IV trials. The results of these clinical trials would be the basis for advancing candidate drugs and devices through development with the ultimate goal of submission to the FDA in support of a New Drug Application (NDA), Premarket notification 510k, Premarket Approval (PMA) or Investigational Device Exemptions (IDE).It is estimated that the new NICHD CCTN will consist of up to 4 sites capable of performing male contraceptive clinical trials and up to 16 female sites. Please be advised that the NICHD is issuing separate RFPs for each CCTN Topic Area (Male Contraceptive Clinical Trials & Female Contraceptive Clinical Trials) and the SCCC for the CCTN. This Pre-Solicitation announcement is for the RFP for the Male Sites for the only.The RFP will be made available electronically only via the FedBizOpps website (http://www.fbo.gov). Offerors are responsible for routinely checking the FedBizOpps website for any possible solicitation amendments that may be issued.
NIH-NICHD-CRHB-2012-04
Department of Health and Human Services National Institutes of Health
Award Notice 1/1
4/2/12, 4:27 PM